Adbiotech

At a glance

Adbiotech filed 141 disclosures in the last 12 months, including 16 5% holder, 5 insider, 3 issuance and 2 m&a. The most recent key filing was on Oct 30: Conversion price ₩1,999; if all converted, equal to 1.6% of shares outstanding.

Revenue for 2025 was ₩12.9B, up 15.8% on 2024. It made an operating loss of ₩3.5B. Debt was 258% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩6B and operating loss of ₩3B.

The 2025 annual report lists 64 employees with an average tenure of 3.6 years and average pay of ₩42.3M, #2031 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩59M each on average. It paid no cash dividend for 2025. 비케이파트너스투자조합1호 and related parties held 20.83% at year end.

Of 5 recent 5%+ holder reports, 4 raised and 1 cut a stake; the largest stake reported was 34.86% on Jun 5.

From the 2025 annual report

Staff: 64 (38 men, 26 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩2.5B. Directors and auditors: 5, paid ₩282M in total.

No cash dividend was paid for 2025.

Largest shareholder

비케이파트너스투자조합1호 holds 20.83%; with 0 related parties the group holds 20.83% of common shares at year end.

Auditor: 우리회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports